Promethera Biosciences Revenue and Competitors

Claim your profile

Mont Saint Guibert, USA



Total Funding



Estimated Revenue & Valuation

  • Promethera Biosciences's estimated annual revenue is currently $4.6M per year.(i)
  • Promethera Biosciences's estimated revenue per employee is $77,500
  • Promethera Biosciences's total funding is $149.1M.

Employee Data

  • Promethera Biosciences has 59 Employees.(i)
  • Promethera Biosciences grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Promethera Biosciences News

2022-04-20 - Ornithine-Transcarbamylase Deficiency Market Size And ...

... Ultragenyx Pharmaceutical Inc, Promethera Biosciences SA, Unicyte AG, Lucane Pharma SA, Translate Bio Inc, Selecta Biosciences Inc.

2022-04-17 - Ornithine Transcarbamylase Deficiency Market Recovery and ...

Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc.

2022-04-17 - Acute On Chronic Liver Failure Market Recovery and Impact ...

Grifols Therapeutics, Promethera Biosciences, RHEACELL, Versantis AG, Martin pharmaceuticals. Report overview: * The report analyses regional...

2019-12-16 - Promethera Receives €7.5M Investment; Closes €47.2M Series D

Promethera Biosciences SA, a Mont-Saint-Guibert, Belgium-based global innovator in cell-based medicines and liver diseases, added €7.5m in funding to its recent €39.7m Series D financing. The round was led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures, with MEDIPAL Hold ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding